



## **Webcast Alert: Aastrom Biosciences, Inc. Presentation At Informed Investors**

### **Biotechnology/Cancer Stocks Virtual Forum To Be Webcast On Thursday, November 4, 2004, 9:30am ET**

**Ann Arbor, MI, November 2, 2004** - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) will present at the following forum:

**What:** R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, Aastrom Biosciences, Inc. (NasdaqSC: ASTM) will give a presentation at Informed Investors Biotechnology/Cancer Stocks Virtual Forum.

Ronald Garren, M.D., Board Certified Internist and Editor of Biotech Insight, will deliver the forum keynote at 9 am.

**When:** November 4, 2004 @ 9:30 AM Eastern Time

**Where:** [http://www.informedinvestors.com/IIF\\_Forum.asp?ForumID=85130](http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85130)

**How:** Live over the Internet-Simply log on to the web at the address above.

**Contact:** Kris Maly or Becky Anderson, Investor Relations Department, Email: [mail@aastrom.com](mailto:mail@aastrom.com) or Phone: (734) 930-5777

If you are unable to attend the live event, the forum will be available via webcast at [http://www.informedinvestors.com/IIF\\_Forum.asp?ForumID=85130](http://www.informedinvestors.com/IIF_Forum.asp?ForumID=85130).

#### **About Aastrom Biosciences, Inc.**

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is a regenerative medicine company developing proprietary adult stem cell-based products for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues. Aastrom's strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products (PCPs), which are now in the clinical stage in the U.S. and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The Company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

**For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).**

Source: Aastrom Biosciences, Inc.

Forum Contact: Cary Loeser, Informed Investors, 804-327-3407, Email: [cloeser@wilink.com](mailto:cloeser@wilink.com), Web site: <http://www.informedinvestors.com>